Zanubrutinib-Rituximab Cuts Progression Risk 43 Percent in Frontline Mantle Cell Lymphoma in Phase 3 MANGROVE Trial
BeOne Medicines' chemo-free BRUKINSA plus rituximab regimen met its primary endpoint against bendamustine-rituximab in untreated mantle cell lymphoma.